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Background: Erufosine is a promising anticancer drug that increases the efficacy of radiotherapy in glioblastoma
cell lines in vitro. Moreover, treatment of nude mice with repeated intraperitoneal or subcutaneous injections of
Erufosine is well tolerated and yields drug concentrations in the brain tissue that are higher than the
concentrations required for cytotoxic drug effects on glioblastoma cell lines in vitro.
Methods: In the present study we aimed to evaluate the effects of a combined treatment with radiotherapy and
Erufosine on growth and local control of T98G subcutaneous glioblastoma xenograft-tumours in NMRI nu/nu mice.
Results: We show that repeated intraperitoneal injections of Erufosine resulted in a significant drug accumulation
in T98G xenograft tumours on NMRI nu/nu mice. Moreover, short-term treatment with 5 intraperitoneal Erufosine
injections caused a transient decrease in the growth of T98G tumours without radiotherapy. Furthermore, an
increased radiation-induced growth delay of T98G xenograft tumours was observed when fractionated irradiation
was combined with short-term Erufosine-treatment. However, no beneficial drug effects on fractionated
radiotherapy in terms of local tumour control were observed.
Conclusions: We conclude that short-term treatment with Erufosine is not sufficient to significantly improve local
control in combination with radiotherapy in T98G glioblastoma xenograft tumours. Further studies are needed to
evaluate efficacy of extended drug treatment schedules.
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Local controlBackground
Despite recent advances in therapy of high-grade glioma
the prognosis of these highly aggressive tumours is still
poor. The high morbidity upon resection of the primary
tumour, the early and widespread infiltration of malig-
nant cells into the surrounding tissue, the rapid progress
and the high intrinsic resistance against chemotherapy
and radiotherapy are major biological factors responsible
for treatment failure. Therefore, researchers aim at the* Correspondence: verena.jendrossek@uni-due.de
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reproduction in any medium, provided the oridentification of drugs that cross the blood–brain barrier
and overcome therapy resistance for improving clinical
outcome for patients suffering from high-grade glioma.
Preclinical data suggest alkylphosphocholines (APC) as
promising compounds for the treatment of brain tumours,
including malignant glioma: Intravenously applicable APCs
like Erufosine cross the blood–brain barrier of rats and
mice upon repeated parenteral administration of tolerable
drug-doses [1,2] and exert potent cytotoxic effects on
human glioblastoma cell lines when given alone or in com-
bination with radiotherapy in vitro [3]. Agents of this drug
family have a particular mechanism of action: In contrast to
DNA-damaging drugs and radiotherapy, they primarily tar-
get cellular membranes thereby affecting signal transduc-
tion pathways involved in the regulation of proliferation,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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relevant compounds including Miltefosine, Erufosine or
Perifosine are potent inhibitors of the phosphatidylinositol-
3-kinase (PI3K)/protein kinase B (Akt) pathway and the
MAPK-pathway, two survival pathways that are frequently
activated in high-grade glioma [5-8]. Moreover, APC induce
apoptosis independently of wild type p53 [9,10] suggesting
activity in p53-deficient glioblastoma cells.
Interestingly, APC increase the efficacy of chemotherapy
and radiotherapy in vitro and in animal experiments [9].
Although the clinical use of the “first generation” APC
Miltefosine (Hexadecylphosphocholine) is restricted to
topical use in the setting of anticancer treatment, because
of haemolytic and gastrointestinal toxicity [11], recent
phase-I trials demonstrated feasibility and tolerability of
pharmacologic therapy with the second generation APCs
Perifosine or Erufosine alone [12-14] as well as of Perifo-
sine in combination with chemotherapy and radiotherapy
for patients with advanced human malignancies [15,16].
Of note, the combination of Perifosine with capecitabine
showed a promising clinical activity in patients with meta-
static colorectal cancer [16]. A potential benefit of Perifo-
sine in combination with radiotherapy is actually being
tested in patients with non-small cell lung cancer [17].
While Perifosine represents an orally applicable APC,
Erufosine is the first clinically relevant intravenously ap-
plicable APC. Due to the cis-double-bond in the alkyl
chain, Erufosine and the closely related Erucylphospho-
choline form lamellar instead of micellar structures in
aqueous solutions and therefore lack haemolytic activity.
Because of modifications in the polar part of the mol-
ecule Erufosine exhibits a better solubility in aqueous
solutions compared to Erucylphosphocholine thereby fa-
cilitating its parenteral injection. On the basis of its po-
tent in vitro activity on glioblastoma cell lines alone and
in combination with ionizing radiation, and its ability to
cross the blood–brain barrier and to accumulate in the
brain tissue we aimed to evaluate the effects of a com-
bination of Erufosine and fractionated irradiation on
growth and local control of T98G glioblastoma xeno-
graft-tumours in immunodeficient mice. The T98G glio-
blastoma cell line was selected as experimental model
because these highly apoptosis-resistant cells were par-
ticularly sensitive to Erufosine-treatment alone and in
combination with radiotherapy in vitro [3].
Methods
Animals, cells, and tumour model
Animal experiments were conducted according to
German animal welfare regulations and approved by the
local authorities (registration number RO 1/05). Immu-
nodeficient NMRI-(nu/nu)-nude mice were purchased
from the University Hospital Essen (age 6–12 weeks).
Animals were housed in an individually ventilated cagerack system (Techniplast, Italy). They were fed with ster-
ile high calorie laboratory food (Sniff, Germany). Drink-
ing water was supplemented with chlorotetracycline and
potassium sorbate acidified to a pH of 3.0 with hydro-
chloric acid and was provided ad libitum.
Xenograft tumours of the human glioblastoma cell line
T98G (ATCC, Bethesda, Maryland, USA) were generated
by injection of 3×106 cells in 300 μl medium (2+1 mix-
ture of RPMI1640/10% FCS with matrigel (BD Bios-
ciences)) into the axilla and serial passage of the
resulting tumours. To obtain optimal suppression of re-
sidual immune activity in the donor mice a whole-body-
irradiation with 4 Gy was performed 2 days before injec-
tion of the tumour cell suspension and before the first
serial passage. For the experiments a source tumour was
excised and tumour pieces of about 2 mm diameter were
transplanted subcutaneously into the right hind limb of
ether-anaesthetized mice (approximately 70% engraft-
ment rate).
For the determination of tumour growth, tumour size
was quantified with calipers in two perpendicular dia-
meters twice a week. The tumour volume (V) was calcu-
lated as V = (a × b2)/2, where a and b are the long
tumour axis and the short tumour axis, respectively.
Body weight was monitored twice a week except for the
treatment time; here, the body weight was recorded
daily. Mice were randomly allocated to the treatment
groups when the tumour volume reached 80–100 mm3.
In the present experiments the median volume doubling
time from the inclusion volume was 6.5 days (5.6; 8.6 d).
Pharmacological treatment
Erufosine (ErPC3, MG 504.7) is the (N,N,N-trimethyl)-
propylammoniumester of erucyl-phosphoric acid. It was
kindly provided by H. Eibl, Max Planck Institute of Bio-
physical Chemistry, Göttingen, Germany. For aqueous
solutions Erufosine was dissolved at 60°C in a mixture of
destilled water and 1.2-Propandiol (Merk, Germany;
mixture 98:2) to a final concentration of 24 mg/ml Eru-
fosine and stored at 5°C after sterile filtration. For intra-
peritoneal or subcutaneous injection this stock solution
was diluted with 0.9% sodium-chlorid solution in the
appropriate ratio to obtain the required Erufosine-
concentration in 100 μl for a body weight of 30 g. Differ-
ence in body weight of the mice were adjusted with
injection volume.
To establish the schedule of Erufosine-treatment for
the present study we analyzed drug-accumulation in
xenograft tumours in preliminary experiments. Eight
intraperitoneal injections of Erufosine every 48h at doses
of 20 mg/kg BW or 40 mg/kg BW yielded tumour con-
centrations of 197 ± 52 nmol/g or 626 ± 76 nmol/g,
respectively (means ± SD; n=4) at the end of Erufosine-
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concentration of 50 nmol/g) known to potently induce
tumour cell death when given as single drug and for in-
creasing the cytotoxic efficacy of ionizing radiation
in vitro [3].
Accordingly, in the experimental study mice were treated
by eight intraperitoneal injections of 40 mg/kg body weight
(BW) Erufosine to a cumulative dose of 320 mg/kg, re-
spectively. Intraperitoneal injection was used as standard
administration route because we showed in our earlier in-
vestigation that intraperitoneal injection was generally well
tolerated whereas repeated subcutaneous injections of
high-dose Erufosine regularly caused local reactions at the
injection site at similar bioavailability although less gastro-
intestinal side effects were observed [1]. If a weight loss be-
tween 5-10% was detected, treatment was continued by
subcutaneous drug administration (21% of injections). If a
weight loss of above 10% was detected upon subcutaneous
injection or animals appeared to suffer (immobility, loss of
appetite, pale skin, retraction of the abdomen), drug treat-
ment was discontinued until recovery and animals were
evaluated as “intent to treat” (1% of injections). The desci-
sion was taken by the responsible scientist (G.H) on the
basis of weight measurement and control of the animal be-
havior before each injection. Control animals received an
intraperitoneal injection of the solvent.
Analysis of ErPC3 in tumour tissues
For the quantification of Erufosine in plasma and tissue
samples liquid chromatography-tandem mass spectrom-
etry (LC-MS/MS) was employed with a deuterium la-
belled analogue (ErPC3-D9, MW 512.82) as internal
standard as described in detail elsewhere [14].
For the analysis of Erufosine-concentrations in subcuta-
neous xenograft tumours, the tumours were removed after
diethylether anaesthesia and immediate cervical distortion
1 day after the end of the Erufosine treatment. The
tumours were weighed and stored at −20°C until analysis.
The Erufosine-concentration was then analyzed using the
frozen tissue samples.
Irradiation treatment, follow up, determination of tumour
growth delay and TCD50 values
Fractionated irradiation was given under ambient condi-
tions with a linear accelerator (6 MV photons, 400cGy
min-1 dose rate) to the tumour on the right hind limb of
the animals as described earlier [18]. Shielding reduced
the dose to the animal body to less then 3% of the pre-
scribed tumour dose.
The study was performed in three different experi-
mental set-ups (Figure 1):
To estimate the irradiation dose for the combination
experiments animals were randomized to 4 treatment
groups receiving no irradiation (n=7), fractionatedirradiation of 5x 2 Gy (n=8), 5x 3.5 Gy (n=7) and 5x 4.5
Gy (n=7) alone (Experiment 1; Figure 1A). The median
tumour volume in this experiment at start of treatment
was 105 mm3 (98; 141 mm3). Follow up was discontin-
ued after 120 days from treatment, in case of intercur-
rent death or if the volume of the progressive or
recurrent tumours reached 8-fold the starting volume.
An exponential regression model was used to interpolate
a modified growth delay endpoint as time after onset of
irradiation treatment needed to achieve 4- and 8-fold
size of the initial tumour volume at the start of treat-
ment for each single tumour. Animals that appeared to
suffer were killed before reaching these endpoints and
were considered as censored at this time-point.
In experiment 2 (Figure 1B), fractionated irradiation
with a fixed radiation dose of 5 × 3.3 Gy was applied in
combination with eight injections of 40 mg/kg BW Eru-
fosine. This Erufosine-dose had been shown earlier to
yield tissue concentrations sufficient to increase the effi-
cacy of ionizing radiation in vitro [1]. Erufosine was
injected daily beginning 5 days prior to irradiation to allow
appropriate accumulation of the drug in the tumour tissue
at the onset of radiotherapy followed by 3 injections of
Erufosine every 48h without or with concomitant fractio-
nated irradiation. Animals were randomized to the follow-
ing treatment groups: i) no irradiation/no Erufosine (n=18),
ii) fractionated irradiation/no Erufosine (n=14), iii) no irradi-
ation/Erufosine (n=21), iv) fractionated irradiation/Erufosine
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were recruited to the experiment with a smaller median
tumour volume of 83 mm3 (81; 91 mm3) compared to the
first experiment in order to achieve comparable tumour
volumes at the onset of irradiation treatment on day 5.
Follow-up was discontinued after 200 days from treatment
of the last set of animals, in case of intercurrent death or if
the volume of the progressive or recurrent tumours reached
8-fold the starting volume. Growth delay after the onset of
Erufosine treatment was determined as described above.
Volume doubling times (VDT) were defined as time
interval between the start of treatment to the day when
the tumour reached twice the initial tumour volume in
case of continuously growing tumours. If a transient re-
gression occurred upon treatment the volume doubling
time was calculated as interval from the first day of in-
crease of tumour volume to the day when the tumour
reached twice the minimal tumour volume.
Experiment 3 was designed to determine the tumour
control probability. For this, a graded top irradiation -
estimated to achieve local tumour control with the
higest top-up dose from experiment 1 - was added after
fractionated irradiations (5 × 3.3 Gy) with and without
40 mg/kg BW Erufosine (Figure 1C). The median
tumour volume in this experiment at start of treatment
was 90 mm3 (87; 108 mm3). Follow up was similar
to the procedure described above. Tumour control
rates at day 200 after the end of treatment were deter-
mined with respect to censored animals as described by
Walker and Suit [19]. Animals with identical treatment
from the second and third experiment were pooled
since no significant difference in corresponding para-
meters occurred.Statistics
For the delineation of the time course of the experi-
ments and of tumour doubling times data are expressed
as median values with the upper and lower 95%-confi-
dence intervals as given by Sachs [20].
Comparison of tumour size or volume doubling time
between groups was done by nonparametric Mann–
Whitney tests in case of two groups and Kruskal-Wallis
tests with Dunn’s post-tests, using GraphPad InStat 3.05
(Graph Pad Software, Inc.). P -values of p ≤ 0.05 were
considered statistically significant.
Growth delay is presented according to the method of
Kaplan and Meier considering achievement of the 4- and
8-fold size of the initial tumour volume as event and tak-
ing animals without the respective tumour volume at the
end of the observation period or undergoing intercurrent
death as censored at that time-point. Differences between
groups were tested for significance by the Wilcoxon-test.
Median growth delay with 95%-confidence intervals wascalculated with lognormal approximation implemented in
JMP 9.0.0W software (SAS institute Inc.).
For estimation of the dose dependent tumour control
probabilities including 95%-confidence intervals (CI), the
results of the top up dose experiments including the
data for control tumours (no cures at 0 Gy) were mod-
elled by using the logit module of a commercial software
package (XLSTAT2011W by Addinsoft SARL).
Arithmetic means with standard deviation are presented
and student0s t-test was applied when appropriate.
Results
Effects of single modality treatment on tumour growth
We first established the appropriate doses of fractio-
nated radiotherapy for the combination experiments
(Figure 1A). Fractionated irradiation of the tumours led
to a dose-dependent delay in tumour growth. Growth
delay to the 4-fold initial tumour volume was 16, 24, 49
and 76 days for untreated controls or 5 fractions of 2
Gy, 3.5 Gy and 4.5 Gy, respectively (Figure 2A/B). The
median growth delay to the 8-fold initial tumour volume
was 29, 40, 59 and 139 days for the same treatment groups
(Figure 2C/D). The growth delay was significant for treat-
ment with 5 × 3.5 Gy and 5 × 4.5 Gy compared to untreated
control tumours. In one out of seven animals the tumour
was controlled locally upon treatment with 5 × 4.5 Gy after
120 days, whereas all other tumours recurred.
In the experimental study mice were treated by eight
intraperitoneal injections to a cumulative dose of 320 mg/kg.
In order to achieve an appropriate Erufosine concentration
within the tumour tissue during the course of radiotherapy
mice were pretreated with 5 daily injections of 40 mg/kg
body weight (BW) Erufosine followed by 3 injections of Eru-
fosine every 48h without or with concomitant fractionated ir-
radiation (Figure 1B). To evaluate the effects of short-term
treatment with Erufosine alone (5 days) the tumour volume
was measured in all animals treated with 40 mg/kg BW Eru-
fosine and all animals without Erufosine administration be-
fore the onset of fractionated irradiation. The mean relative
tumour volume after 4 days of treatment with 40 mg/kg
Erufosine alone compared to the starting volume (1.0) was
1.42 ± 0.39 (n=64) whereas the relative volume of the
tumours in the untreated control group amounted to 1.77
± 0.63 (n=55). These data are based on the individual in-
crease in tumour volume and provide evidence that short-
term treatment with Erufosine alone causes a significant
growth-inhibition in T98G xenograft tumours (p< 0.05).
Effects of combination therapy on tumour growth and
local control rates
To detect a beneficial effect of a combined treatment
with signal transduction inhibitors and radiotherapy it
is important to use a radiation dose which induces a sig-









































































Figure 2 Effects of single radiation treatment on tumour growth. A Modified growth delay to four-fold of starting volume after fractionated
irradiation. Given are Kaplan-Meier-plots of tumours after treatment with increasing doses of fractionated irradiation (open diamonds, control;
grey diamonds, 5 x 2 Gy; dark grey diamonds, 5 × 3.5 Gy; black diamonds, 5 × 4.5 Gy). B Respective computed median growth delay with 95%-
confidence interval (n=7-8), * indicates p<0.05 vs. control. C Modified growth delay to eight-fold of starting volume after fractionated irradiation.
Given are Kaplan-Meier-plots of tumours after treatment with increasing doses of fractionated irradiation (open diamond, control; grey diamond,
5 × 2 Gy; dark grey diamond, 5 × 3.5 Gy; black diamond 5 × 4.5 Gy). D Respective computed median growth delay with 95%-confidence interval
(n=7-8), * indicates p<0.05 vs. control.
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the basis of the results from Experiment 1 we selected a
dose of 3.3 Gy per fraction. To gain insight into treatment-
related toxicity we recorded the median relative weight of
the nude mice in the four treatment groups. Radiation
alone failed to induce a relevant weight loss whereas treat-
ment with 40 mg/kg BW Erufosine alone or in combin-
ation with fractionated irradiation led to a transient
median weight loss of about 10% (data not shown). Also
the number of Erufosine-treated mice that died during
treatment was equal in the nonirradiated and irradiated
treatment groups (in total 6 out of 78 mice; 7%). These
observations reveal that the addition of fractionated irradi-
ation to the Erufosine treatment does not cause unex-
pected additional toxicity.
The course of the median tumour volume in the four
treatment groups is depicted in Figure 3. As expected,
fractionated irradiation with 5 × 3.3 Gy led to a transientdecrease in median tumour volume and a delay in
tumour growth which became significant after 14 days.
However, the transient early growth delay observed dur-
ing short-term treatment with Erufosine alone was not
maintained upon discontinuation of drug treatment in
the longer follow-up and no decrease in tumour volume
was detected upon Erufosine treatment without irradi-
ation. Nevertheless, the addition of Erufosine qualita-
tively enhanced the decrease in tumour volume induced
by radiotherapy alone, yielding significant differences
when the irradiation groups were compared (Figure 3).
In line with these results, the median growth delay
until completion of the 4- and 8-fold initial tumour vol-
ume significantly increased after fractionated irradiation.
Again, laying emphasis on the early observation period,
a trend (Wilcoxon-Test p=0.08) to an increased tumour
growth delay was observed when Erufosine treatment
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Figure 3 Effects of combination treatment on relative tumour
volume. Animals received no irradiation combined with 8 injections
of vehicle (open black circles, n=18) or 40 mg/kg BW Erufosine (red
circles, n=21). Alternatively, animals received fractionated irradiation
(5 × 3.3 Gy) combined with 8 injections of vehicle (open white
squares, n=14) or 40 mg/kg BW Erufosine (red squares, n=20).
Erufosine was given daily before the onset of radiotherapy and
every 48h during the course of fractionated irradiation. Grey bar
notifies treatment time. * indicates p<0.05 vs. control, # indicates
p<0.05 vs. irradiation alone. Median relative tumour volume is given
with upper and lower 95% confidence intervals.
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initial tumour volumes upon Erufosine-treatment
amounted to 14 and 25 days compared to 15 and 27
days in the untreated controls without irradiation and 82
and 105 days compared to 63 and 94 days in the con-
trols with irradiation.
In contrast, considering the volume doubling times of
re-growing tumours, no significant differences were
found when treated tumours with transiently decreased
growth were compared with untreated continuously
growing controls. In fact, the median volume doubling
times were 6.0 (95% CI: 3.7;8.2), 6.6 (4.9;8.3), 9.2 (4.4;
21.0) and 8.6 (6.3;13.5) days for untreated controls, Eru-
fosine alone, fractionated irradiation alone and combin-
ation therapy, respectively (Figure 5A).
In the final experimental set-up, we analyzed the
tumour control rates after additional top up irradiations
(Figure 1C). Single doses of 0, 5, 11.4, 19.8 and 30.6 Gy
following fractionated irradiation with 5 × 3.3 Gy
achieved control rates of 29%, 33%, 50%, 67% and 100%
without Erufosine treatment and 24%, 20%, 14%, 83%
and 100% upon Erufosine treatment (Figure 5B). The
resulting TCD50 values from the calculated tumour con-
trol probabilities were 27.0 (21.1; 36.8) Gy in the absence
of Erufosine and 29.5 (23.8; 39.2) Gy in the presence of
Erufosine showing no significant difference. Altogether,
these data reveal that the trend to increased efficacy
of ionizing radiation in combination with short-time
Erufosine treatment observed in the combinationexperiment with respect to growth delay and transient
tumour volume reduction had no impact on treatment
efficacy in terms of tumour control.
Discussion
In the present investigation, we show for the first time
that short-term treatment with the intravenously applic-
able Erufosine causes a transient decrease in the growth
of the T98G glioblastoma tumours. This effect was asso-
ciated with a significant accumulation of Erufosine in
the xenograft T98G tumours upon repeated drug applica-
tions. Moreover, we observed a trend to an enhanced
radiation-induced growth delay of T98G xenograft tumours
when fractionated irradiation was combined with short-
term Erufosine-treatment. However, these effects failed to
translate into beneficial drug effects on fractionated radio-
therapy in terms of local tumour control.
We show that repeated parenteral injections of 20 or
40 mg/kg BW Erufosine result in a significant
accumulation of this membrane-targeted agent in T98G
xenograft tumours. This corroborates findings of Vink
and co-workers showing accumulation of the closely
related compound Perifosine in KB squamous cell car-
cinoma xenograft tumours upon repeated oral drug ad-
ministration [21]. Interestingly, short-term treatment
with Erufosine caused a transient growth-inhibition
within 5 days. However, the tumours resumed growth
within a few days after discontinuation of drug treat-
ment. This suggests that although the drug reaches con-
centrations in the tumour tissue that are sufficient for
cytostatic and/or cytotoxic effects in vivo this treatment
schedule is not sufficient to eradicate a considerable
number of clonogenic tumour cells and thus, tumour
stem cells. In line with our findings a recent study
showed growth inhibitory effects of treatment with the
closely related Perifosine in another glioma xenograft
model (U251). Since the growth delay described by the
authors was more pronounced compared to the results
obtained in our study we speculate that the higher cu-
mulative dose (475 mg/kg) of Perifosine upon oral ad-
ministration may be responsible for the improved drug
action [22]. Similarly, Li et al. [23] detected a substantial
growth delay in neuroblastoma xenograft tumours in
nude mice upon a 30-day treatment with Perifosine.
These data suggest that in vivo efficacy of these com-
pounds may depend on an extended treatment schedule.
Otherwise, the heterogeneous outcome of preclinical
and clinical studies with Perifosine implicates that the
efficacy of treatment with the membrane-targeted APC
also largely depends on the cell type. Whereas extended
treatment with Perifosine was without single drug effect
in prostate cancer xenografts in vivo [24] and no evident
clinical effect of Perifosine was seen in pancreatic cancer,














































Figure 4 Effect of combination treatment on tumour growth delay. A Modified growth delay to four-fold of starting volume after combined
treatment. Given are Kaplan-Meier-plots of mock-irradiated tumours combined with vehicle (open black diamonds) or 40 mg/kg BW Erufosine
(open red squares) and 5 × 3.3 Gy combined with vehicle (closed black diamonds) or 40 mg/kg BW Erufosine (closed red squares). B Respective
computed median growth delay of data obtained in A) with 95%-confidence interval (n=14-18). C Modified growth delay to eight-fold of starting
volume after combined treatment. Given are Kaplan-Meier-plots of mock- irradiated tumours combined with vehicle (open black diamonds) or 40
mg/kg BW Erufosine (open red squares) and 5 × 3.3 Gy combined with vehicle (closed black diamonds) or 40 mg/kg BW Erufosine (closed red
squares). D Respective computed median growth delay of data obtained in C) with 95%-confidence interval (n=14-18).
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tivity in hematological malignancies [29] and to some
extent in soft tissue sarcoma or prostate cancer [30,31].
We also found that T98G xenograft tumours respond to
fractionated irradiation with a dose-dependent tumour
growth delay. Already with doses of 5 × 3.5 Gy (17.5 Gy
total dose) we observed a significant tumour growth delay
compared to the non-irradiated controls. This corrobo-
rates earlier findings showing exceptional in vivo radiation
sensitivity of this glioblastoma cell line but is in contrast
to the clinical experience of high radiation resistance in
glioblastoma tumours [32-34].
The combination of fractionated irradiation with 8 par-
enteral injections of 40 mg/kg BW Erufosine 4 days before
and during the fractionated irradiation was obviously able
to intensify the radiation-induced decrease in tumour vol-
ume. The failure to detect more than borderline signifi-
cant differences in the growth-delay of tumours treated
with fractionated irradiation alone and fractionated irradi-
ation plus Erufosine may at least partially be due to theunexpected high rate of local tumour control rates that were
observed in response to fractionated irradiation alone in the
combination experiment 1): Only a low rate of local controls
(14%) had been observed in the dose-finding experiment in
the highest dose-group (5 × 4.5 Gy) and no local controls
had been observed in the 5 × 3.5 Gy dose-group. In contrast,
a largely increased rate of local controls (28.6%) was
observed in the combined treatment experiment (experi-
ment 2) upon fractionated irradiation with a dose of 5 × 3.3
Gy. The reason for the discrepancy between the two experi-
ments is unknown. Only 66% of transplanted animals devel-
oped subcutaneous T98G tumours which may be indicative
of a residual antitumour immunoreactivity in the NMRI nu/
nu mice [35]. But Krause and coworkers had already
demonstrated in an earlier study that TCD50 values for
T98G tumours do not differ in mice that received whole
body irradiation prior to implantation of the xenograft
tumours [34]. Therefore, we assume that a residual immune
response of the host may not be causative for the differential







































Figure 5 Effect of combination treatment on volume doubling
time and tumour control. A Volume doubling time (VDT) for
progression or re-growth of individual tumours after irradiation with
5 × 3.3 Gy (black circles) or without irradiation (white circles) and
treatment with vehicle or 40 mg/kg BW Erufosine as indicated.
Horizontal lines indicate median values of the treatment groups.
B Local tumour control rates and calculated tumour control
probabilities after fractionated irradiation with 5 × 3.3 Gy and
graded top up doses (0–30.6 Gy) combined with injection of 40 mg/
kg BW Erufosine (closed red circles) or vehicle (open black triangles).
Thin lines indicate 95%-confidence intervals, size of symbols reflects
number of animals (n=5-21).
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term Erufosine treatment to fractionated irradiation
would improve tumour control probability by measuring
the tumour control rates after additional top up irradia-
tions we found that short-term Erufosine failed to im-
prove the outcome of fractionated radiotherapy in terms
of local tumour control. This suggests that although
tumour regrowth was slightly retarded by co-treatmentwith erufosine no additional effect on the eradication of
clonogenic tumour stem cells could be achieved.
Notably, the TCD50 value for T98G xenografts detected
in the present study (12 Gy Top-up irradiation dose and a
total irradiation dose of about 30 Gy under ambient condi-
tions) was in the range of the TCD50 values reported in
earlier studies for T98G xenografts after single dose or
fractionated irradiation [33,34,36] although a comparison
between the different studies remains difficult due to var-
iations in the irradiation scheme (single/fractionated/
mixed) and oxygenation conditions (ambient/hypoxic).
In the present study, Top-up dose irradiations were admi-
nistered under ambient conditions. Therefore, the lack of
a difference in tumour control experiments in spite of
a significant effect of Erufosine in growth delay experi-
ments may be due to an increase of tumour hypoxia at the
stem cell level induced by Erufosine during fractionated
radiotherapy.
Up to now, only few studies are available that tested a
potential benefit of APC in combination with radiother-
apy in vivo. However, those studies were restricted to
the use of the orally available APC Perifosine and the
evaluation of tumour growth delay. Consistent with our
observations with the novel intravenously applicable
APC Erufosine, De la Pena et al. [22] observed a growth
delay of U251 glioblastoma xenografts after repeated
oral administrations of the closely related alkylphospho-
choline Perifosine but also failed to detect an increased
efficacy when Perifosine-treatment was combined with a
single dose of 4 Gy at the onset of drug treatment. Given
the comparable in vivo radiosensitivity of the two glio-
blastoma cell lines T89G and U251 [33] the irradiation
dose used might be too low for a sustained combination
effect, although a growth delay of single modality treat-
ment was detectable.
In contrast, the same protocol of Perifosine-treatment
combined with 2 × 5 Gy on days 2 and 4 caused a signifi-
cant growth delay in a prostate cancer xenograft model
compared to untreated controls whereas the single mo-
dality treatment was not effective [24]. Notably, even a
sustained tumour regression was demonstrated after
combined treatment with Perifosine and irradiation
(5 Gy on days 2 and 4) in xenografts of squamous cell
carcinoma [37]. Importantly, in this study effectiveness
of Perifosine-treatment depended on the treatment dur-
ation and cumulative drug dose.
Also, the following limitations of the preclinical models
have to be carefully considered: (i) In vitro radiosensitivity
does not necessarily correlate to the tumour control prob-
abilities determined in vivo [33]. (ii) Translation of find-
ings from xenograft models to the clinical situation is even
more difficult, particularly in the case of high-grade gli-
oma, because of obvious differences in the tumour micro-
environment and the growth behaviour of the malignant
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underestimate additional modes of drug action, such as in-
hibition of migration and invasion and antiangiogenic
effects [39-42]. However, up to now the use of more ap-
propriate preclinical models for the evaluation of the effi-
cacy of combined treatment approaches with radiotherapy
in vivo, e.g. orthotopic or spontaneous tumours, is still
sparse because of the limited availablity of image-guided
radiation systems for small animals.
In conclusion, the intervenously applicable APC Eru-
fosine with proven ability to cross the blood brain bar-
rier causes a transient decrease in the growth of T98G
glioblastoma tumours in vivo but fails to improve effi-
cacy of fractionated irradiation in terms of local tumour
control. Further in vivo studies are needed to evaluate
whether extended Erufosine treatment may be more ef-
fective in terms of radiosensitization and whether the
drug may interfere with the known adverse biological
factors that limit the efficacy of radiotherapy in vivo.
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